Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Stock Has Consensus Price Target of $39.00 According to Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $39.00.

Several equities research analysts have recently commented on the company. Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st.

Artiva Biotherapeutics Stock Down 3.0%

Shares of ARTV opened at $7.49 on Friday. The company has a 50-day simple moving average of $10.50 and a 200-day simple moving average of $9.19. The company has a market capitalization of $366.19 million, a PE ratio of -2.27 and a beta of 2.18. Artiva Biotherapeutics has a 52-week low of $2.71 and a 52-week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, hitting analysts’ consensus estimates of ($0.63). On average, research analysts anticipate that Artiva Biotherapeutics will post -2.62 EPS for the current year.

Insider Transactions at Artiva Biotherapeutics

In other news, CEO Fred Aslan sold 23,429 shares of Artiva Biotherapeutics stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $10.92, for a total transaction of $255,844.68. Following the completion of the transaction, the chief executive officer owned 1,449,765 shares of the company’s stock, valued at $15,831,433.80. The trade was a 1.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 120,582 shares of the firm’s stock in a transaction that occurred on Tuesday, July 21st. The stock was acquired at an average price of $9.55 per share, for a total transaction of $1,151,558.10. Following the completion of the transaction, the director directly owned 17,098,479 shares in the company, valued at approximately $163,290,474.45. This represents a 0.71% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders bought 373,327 shares of company stock valued at $3,645,857 and sold 32,080 shares valued at $359,739. Corporate insiders own 1.80% of the company’s stock.

Institutional Trading of Artiva Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. 5AM Venture Management LLC purchased a new position in Artiva Biotherapeutics during the second quarter worth $22,827,049. Blue Owl Capital Holdings LP purchased a new stake in shares of Artiva Biotherapeutics in the second quarter valued at $8,483,000. BlackRock Inc. acquired a new stake in shares of Artiva Biotherapeutics during the second quarter valued at $6,739,000. Nantahala Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics during the second quarter valued at $2,910,000. Finally, Alyeska Investment Group L.P. increased its position in Artiva Biotherapeutics by 173.6% during the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after purchasing an additional 173,615 shares in the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s platform is designed to produce off-the-shelf NK cell treatments that can be manufactured at scale and administered without requiring cells to be collected from each individual patient.

Artiva’s lead product candidate, AlloNK, also known as AB-101, is an investigational allogeneic NK cell therapy intended to target and eliminate antibody-coated cells.